What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation?

被引：54

作者：

Ahrens, Ingo ^{[1
]}

Lip, Gregory Y. H. ^{[2
]}

Peter, Karlheinz ^{[3
]}

机构：

[1] Univ Klin, D-79106 Freiburg, Germany

[2] Univ Birmingham, Ctr Cardiovasc Sci, City Hosp, Birmingham, W Midlands, England

[3] Baker IDI Heart & Diabet Inst, Melbourne, Vic, Australia

来源：

THROMBOSIS AND HAEMOSTASIS | 2011年 / 105卷 / 04期

关键词：

DABIGATRAN; WARFARIN; SAFETY; RIVAROXABAN; RATIONALE; INHIBITOR; APIXABAN; EFFICACY; DESIGN;

D O I：

10.1160/TH10-12-0808

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：574 / 578

页数：5

共 24 条

[21]

Ruiz- Nodar JM, 2010, CHEST

[22] Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development [J].

Ufer, Mike .

THROMBOSIS AND HAEMOSTASIS, 2010, 103 (03) :572-585

[23] Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial [J].

Wallentin, Lars ;

Yusuf, Salim ;

Ezekowitz, Michael D. ;

Alings, Marco ;

Flather, Marcus ;

Franzosi, Maria Grazia ;

Pais, Prem ;

Dans, Antonio ;

Eikelboom, John ;

Oldgren, Jonas ;

Pogue, Janice ;

Reilly, Paul A. ;

Yang, Sean ;

Connolly, Stuart J. .

LANCET, 2010, 376 (9745) :975-983

[24]

AVERROES APIXABAN YI

← 1 2 3 →